One striking chart shows why pharma companies are fighting legal marijuana

Posted on by WOCredentials

“Our findings and existing clinical literature imply that patients respond to medical marijuana legislation as if there are clinical benefits to the drug, which adds to the growing body of evidence suggesting that the Schedule 1 status of marijuana is outdated,” the study concludes.”

Read more…

Related Posts

Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study (2013)

“a short course (8 weeks) of THC-rich cannabis produced significant clinical, steroid-free benefits to 10 of 11 patients with active Crohn’s disease, compared with placebo, without side effects.” Naftali, T., […]

Cannabinoids Decrease the Th17 Inflammatory Autoimmune Phenotype (2013)

“Here we show that the main psychoactive cannabinoid, Δ-9-tetrahydrocannabinol (THC), and the main nonpsychoactive cannabinoid, cannabidiol (CBD), markedly reduce the Th17 phenotype which is known to be increased in inflammatory […]

Cannabinoids and the immune system: an overview (2010)

“Cannabinoids can modulate immune reactions in the periphery but also in the brain, influence T cell subset balance and cytokine expression and play a role in the balance between neuroinflammation […]